Supplemental material
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 24, 2024 - Issue 5
Review
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review
Sudewi Mukaromah Khoirunnisaa Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;b Research Institute Science in Healthy Aging and healthcaRE, Groningen, the Netherlands;c Department of Pharmacy, Institut Teknologi Sumatera, Lampung Selatan, IndonesiaCorrespondence[email protected] [email protected]
https://orcid.org/0000-0002-7687-202XView further author information
https://orcid.org/0000-0002-7687-202XView further author information, , Didik Setiawane Faculty of Pharmacy, Universitas Muhammadiyah Purwokerto, Banyumas, Indonesia;f Center for Health Economic Studies, Universitas Muhammadiyah Purwokerto, Banyumas, Indonesiahttps://orcid.org/0000-0001-9104-548XView further author information
https://orcid.org/0000-0001-9104-548XView further author information &